EA202193276A1 - Способы лечения холангиокарциномы - Google Patents

Способы лечения холангиокарциномы

Info

Publication number
EA202193276A1
EA202193276A1 EA202193276A EA202193276A EA202193276A1 EA 202193276 A1 EA202193276 A1 EA 202193276A1 EA 202193276 A EA202193276 A EA 202193276A EA 202193276 A EA202193276 A EA 202193276A EA 202193276 A1 EA202193276 A1 EA 202193276A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cholangiocarcinoma
patient
methods
treatment
ingratinib
Prior art date
Application number
EA202193276A
Other languages
English (en)
Inventor
Риккардо Паникуччи
Майкл Монтэйт
Ганг Ли
Сьюзан Арэнджио
Крейг Берман
Майкл Хаулэнд
Дэниел Мулрини
Карл Дамбковски
Original Assignee
Квед Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Квед Терапьютикс, Инк. filed Critical Квед Терапьютикс, Инк.
Publication of EA202193276A1 publication Critical patent/EA202193276A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

В рамках настоящего изобретения предусматриваются способы лечения прогрессирующей или метастазирующей холангиокарциномы у пациента путем введения пациенту инфигратиниба или его фармацевтически приемлемой соли, где у пациента произошло прогрессирование холангиокарциномы после предшествующего проведения другой терапии.
EA202193276A 2019-05-28 2020-05-28 Способы лечения холангиокарциномы EA202193276A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853431P 2019-05-28 2019-05-28
PCT/US2020/034881 WO2020243273A2 (en) 2019-05-28 2020-05-28 Methods of treating cholangiocarcinoma

Publications (1)

Publication Number Publication Date
EA202193276A1 true EA202193276A1 (ru) 2022-03-29

Family

ID=73552268

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193276A EA202193276A1 (ru) 2019-05-28 2020-05-28 Способы лечения холангиокарциномы

Country Status (12)

Country Link
US (1) US20220233536A1 (ru)
EP (1) EP3976042A4 (ru)
JP (1) JP2022534742A (ru)
KR (1) KR20220092455A (ru)
CN (1) CN114144180A (ru)
AU (1) AU2020284558A1 (ru)
CA (1) CA3141869A1 (ru)
EA (1) EA202193276A1 (ru)
IL (1) IL288353A (ru)
MX (1) MX2021014523A (ru)
SG (1) SG11202112902YA (ru)
WO (1) WO2020243273A2 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023023935A2 (pt) * 2021-05-19 2024-01-30 Janssen Pharmaceutica Nv Inibidores de tirosina quinase de fgfr para o tratamento de tumores sólidos avançados

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150658A1 (en) * 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
CN114144180A (zh) 2022-03-04
EP3976042A2 (en) 2022-04-06
AU2020284558A1 (en) 2022-01-06
IL288353A (en) 2022-01-01
MX2021014523A (es) 2022-05-19
SG11202112902YA (en) 2021-12-30
WO2020243273A3 (en) 2021-01-07
US20220233536A1 (en) 2022-07-28
JP2022534742A (ja) 2022-08-03
EP3976042A4 (en) 2023-06-28
WO2020243273A9 (en) 2022-02-10
KR20220092455A (ko) 2022-07-01
CA3141869A1 (en) 2020-12-03
WO2020243273A2 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
PH12016502354A1 (en) Pharmaceutical composition
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2022000143A (es) Metodos novedosos.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA202193276A1 (ru) Способы лечения холангиокарциномы
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EA202193211A1 (ru) Лечение синуклеопатий
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2023006765A (es) Metodo para proporcionar terapia de celiprolol a un paciente.
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
UA96488U (ru) Способ лечения нарушений гемоваскулярного гемостаза у больных ишемической болезнью сердца